ENPP-1 Antibody [DyLight 405]

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase family member 1) is a type II transmembrane glycoprotein which is implicated in membrane surface ATP hydrolysis, regulation of pyrophosphate levels, bone mineralization as well as soft tissue calcification. ENPP1 negatively regulates bone mineralization by hydrolyzing extracellular nucleotide triphosphates (NTPs) to produce inorganic pyrophosphate (PPi, an inhibitor of mineralization), whereas tissue-nonspecific ALP positively regulates mineralization by hydrolyzing NTPs and PPi to produce extracellular concentrations of inorganic phosphate (Pi, a substrate for mineralization). ENPP1 is expressed on outer surfaces of mineralizing cells, such as osteoblasts and chondrocytes, and on the membranes of osteoblast- and chondrocyte-derived matrix vesicles. It also hydrolyzes other NTPs such as GTP, CTP, TTP, UTP etc. to their corresponding monophosphates with the release of PPi and diadenosine polyphosphates, and also 3',5'-cAMP to AMP, and may also regulate the availability of nucleotide sugars in ER/Golgi complex, as well as the regulation of purinergic signaling. ENPP1 binds directly to INSR for inhibiting insulin signaling and ENPP1's K173Q/ K121Q polymorphism is associated with insulin resistance, NIDDM, and obesity. Defective ENPP1 causes increased susceptibility for ossification of the posterior longitudinal ligament of spine (OPLL), arterial calcification of infancy, generalized, type 1 (GACI1), obesity/glucose intolerance/NIDDM, and rickets hypophosphatemic autosomal recessive type 2 (ARHR2).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB600-816V

• ENPP-1 Antibodies
• ENPP-1 ELISA Kits
• ENPP-1 Lysate
• ENPP-1 Proteins
• ENPP-1 Proteins and Enzyme